Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Unity Biotechnology, Inc.

Unity Biotechnology is harnessing pathways of aging biology to develop new medicines, focusing on retinal diseases. Self-described as at the forefront of developing a new class of therapeutics that aim to restore diseased tissue to a healthier state.

COM:UNITYBIOTECHNOLOGY

Unity Biotechnology

Last Close

1.17

21/11 21:00

Market Cap

24.34M

Beta: -

Volume Today

51.60K

Avg: -

Financials Not Available